Searched for
ELI LILLY OBESITY DRUG RIVALRY
Nestle to cut artificial colourings from all products by end-2026Nestle is set to eliminate all artificial food colorings globally by the end of 2026, a significant move by the major food producer. This i...- 'Cheaper than a gym, but still not selling': Nithin Kamath on why Indians aren't embracing popular weight-loss drugsDespite rising obesity and affordable generic GLP-1 drugs, India lags in adoption. Nithin Kamath highlights patient retention challenges wi...
- Dow Jones hits record above 52,000 as Alphabet debuts in index, S&P 500 climbs and Nasdaq jumps over 2% as tech stocks lead Wall Street rally - here's how US stock market performed today (June 29)S&P 500, Dow Jones and Nasdaq today June 29: The US stock market started the shortened trading week with solid gains as the Dow Jones close...
- Myanmar overtakes Afghanistan as top illicit opium source; NCB flags India riskMyanmar has become the world's top source of illicit opium, surpassing Afghanistan due to its ongoing civil war and economic crisis. This s...
- Kiran Mazumdar-Shaw warns against long-term GLP-1 use, urges caution over weight-loss drugs, says 'for those who are not diabetic or clinically obese...'Nithin Kamath questions India's slow adoption of affordable GLP-1 weight-loss drugs, despite rising obesity. He points to challenges like l...
- India’s GLP-1 boom loses steam as price war, weak retention hit generic weight-loss drug salesInitial excitement for India's generic weight-loss drugs is fading. Domestic manufacturers are lowering sales targets due to slower-than-ex...
- Centre set to tighten oversight of pharma packaging materialsIndia is set to implement a mandatory registration for printed pharmaceutical packaging manufacturers to combat counterfeit drugs. This mov...
- Eli Lilly launches cancer drug Tanstrive in IndiaThe launch follows marketing authorisation from the Central Drugs Standard Control Organisation (CDSCO) for patients with locally advanced ...
- Pfizer CFO Dave Denton to leave company in AugustPfizer's finance chief Dave Denton is leaving on August 15. Cecile Guegan will be the interim chief financial officer. Denton's departure r...
- Kiran Mazumdar-Shaw eyes crown of world’s top insulin supplier for BioconIndian drugmaker Biocon aims to be the world's top insulin supplier within five years, capitalising on growing demand as major pharmaceutic...
- Global drugmakers rush to boost US presence as tariff threat loomsGlobal drug companies are boosting U.S. production and stockpiling medicines. This is a response to potential tariffs on branded drugs. Com...
- The hidden cost of looking better: What health insurance covers, and what it leaves you to payRising demand for weight-loss drugs, cosmetic procedures and wellness treatments is creating a growing out-of-pocket healthcare expense cat...
- India's Electronics Mart eyes new markets as tech hubs fear job lossesElectronics Mart India is diversifying its store presence beyond Hyderabad due to concerns about potential AI-driven job losses impacting c...
- Eli Lilly's Alzheimer's drug donanemab approved in India, but neurologists flag cost, access barriersA new drug for Alzheimer's, donanemab, has arrived in India. It aims to slow the disease's progression by clearing brain plaques. While off...
- India's weight-loss drug boom raises questions over healthcare prioritiesIndia's market for cheaper anti-obesity drugs has surged tenfold. While demand is high, especially among those with diabetes, concerns abou...
- UK approves Novo weight-loss pill to edge open European marketBritain's medicine regulator has approved Novo Nordisk's weight-loss pill. This makes the UK the first European market for the oral treatme...
- US stocks: S&P 500, Nasdaq end up as tech, chipmakers reboundU.S. stocks largely rose Monday, with the Nasdaq and chipmakers leading the gains as investors sought bargains after Friday's selloff. Reli...
- US stocks: Lilly shares rise on hopes that next-gen drug will extend lead in weight-loss marketLilly presented full data from two retatrutide trials, one in treatment naive type 2 diabetes patients and another in patients with obesity...
- US stocks today: US market gains as semiconductor stocks rebound, Middle East tensions easeMajor Wall Street indexes saw a strong rebound. This recovery was driven by gains in chip stocks. Signs of de-escalation in Middle East ten...
- Eli Lilly says next-gen obesity drug curbs sleep apnea, among other benefitsEli Lilly presented trial results for its new obesity drug retatrutide. The drug significantly reduced sleep apnea severity and knee osteoa...
Load More
